All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This is a study looking at all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (AML).
Acute Myeloid Leukemia
DRUG: Cytarabine|DRUG: Idarubicin|DRUG: All-trans retinoic acid|DRUG: Mitoxantrone|DRUG: Etoposid
event-free survival, two years
kind, incidence, severity, temporal sequence and correlation of side effects of the study drugs, during therapy|complete remission (CR) rate after induction therapy, after second induction cycle|cumulative incidence of relapse, two years|cumulative incidence of death, two years|overall survival, two years
First Induction Therapy:

* Cytarabine 100 mg/m² cont. i.v. days 1-5
* Idarubicin 12 mg/m² i.v. days 1, 3

  * ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28

Second Induction Therapy:

* Cytarabine 100 mg/m² cont. i.v. days 1-5
* Idarubicin 12 mg/m² i.v. days 1, 3

  * ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28

First Consolidation Therapy:

* Cytarabine 1000 mg/m² bid i.v. days 1-3
* Mitoxantrone 10 mg/m² i.v. days 2, 3

  * ATRA 15 mg/m² p.o. days 4-28

Second Consolidation Therapy

* Etoposide 100 mg/m² i.v. days 1-5
* Idarubicin 12 mg/m² i.v. days 1,3

  * ATRA 15 mg/m² p.o. days 4-28